Yili Chuanning Biotechnology Co.,Ltd. (SHE:301301)

SHE:301301 Revenue

Yili Chuanning Biotechnology had revenue of 785.08M CNY in the quarter ending September 30, 2026, a decrease of -27.80%. This brings the company's total for the last twelve months to 4.06B, down -14.25% year-over-year. In the year 2025, Yili Chuanning Biotechnology had annual revenue of 4.62B, down -19.83%. That makes Yili Chuanning Biotechnology the 9,715th largest company in the world by revenue and 1,548th in China.

• Revenue (ttm): 4.06B
• Revenue Growth: -14.25%
• P/S Ratio: 4.29
• Revenue / Employee: 1.30M
• Employees: 3,126
• Market Cap: 17.41B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Medicine Manufacturing 4.23B 91.6%
• Unallocated Other 389.55M 8.4%

By Geography

Chart

• East China 1.87B 40.5%
• North China 884.49M 19.2%
• Export 624.44M 13.5%
• South China 490.59M 10.6%
• Northwest 405.23M 8.8%
• Central China 230.71M 5.0%
• Southwest 86.77M 1.9%
• Northeast 23.30M 0.5%

Fiscal year ended Dec 31, 2025 See the full SHE:301301 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	4.62B	-1.14B	-19.83%
Dec 31, 2024	5.76B	934.97M	19.38%
Dec 31, 2023	4.82B	1.00B	26.24%
Jan 1, 2023	3.82B	588.64M	18.21%
Jan 1, 2022	3.23B	-417.40M	-11.44%

Data Source: S&P Global Market Intelligence Last updated: Oct 22, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 23, 2026

Data Sources Report a data error